Targeting PEAK1 sensitizes anaplastic thyroid carcinoma cells harboring BRAF < sup > V600E < /sup > to Vemurafenib by Bim upregulation

In conclusion, vemurafenib resistance in ATC cells harboring BRAFV600E is associated with PEAK1 activation, resulting in the inhibition of pro-apoptotic Bim protein. Therefore, targeting PEAK1 may be an effective strategy to sensitize ATC harboring BRAFV600E to vemurafenib.PMID:38284248 | DOI:10.14670/HH-18-705
Source: Histology and Histopathology - Category: Cytology Authors: Source Type: research